Implantable cardioverter-defibrillator therapy to reduce sudden cardiac death in adults with congenital heart disease: A registry study.
adult congenital heart disease
implantable cardioverter-defibrillator
sudden cardiac death
Journal
Journal of cardiovascular electrophysiology
ISSN: 1540-8167
Titre abrégé: J Cardiovasc Electrophysiol
Pays: United States
ID NLM: 9010756
Informations de publication
Date de publication:
08 2020
08 2020
Historique:
received:
11
03
2020
revised:
01
06
2020
accepted:
21
06
2020
pubmed:
26
6
2020
medline:
29
7
2021
entrez:
26
6
2020
Statut:
ppublish
Résumé
The adult congenital heart disease (ACHD) population is rapidly expanding. However, a significant proportion of these patients suffer sudden cardiac death. Recommending implantable cardioverter-defibrillator (ICD) insertion requires balancing the need for appropriate therapy in malignant arrhythmia against the consequences of inappropriate therapy and procedural complications. Here we present long-term follow-up data for ICD insertion in patients with ACHD from a large Level 1 congenital cardiac center. All patients with ACHD undergoing ICD insertion over an 18-year period were identified. Data were extracted for baseline characteristics including demographics, initial diagnosis, ventricular function, relevant medication, and indication for ICD insertion. Details regarding device insertion were gathered along with follow-up data including appropriate and inappropriate therapy and complications. A total of 136 ICDs were implanted during this period: 79 for primary and 57 for secondary prevention. The most common congenital cardiac conditions in both groups were tetralogy of Fallot and transposition of the great arteries. Twenty-two individuals in the primary prevention group received appropriate antitachycardia pacing (ATP), 14 underwent appropriate cardioversion, 17 received inappropriate ATP, and 15 received inappropriate cardioversion. In the secondary prevention group, 18 individuals received appropriate ATP, 8 underwent appropriate cardioversion, 8 received inappropriate ATP, and 7 were inappropriately cardioverted. Our data demonstrate low complication rates, particularly with leads without advisories. ICD insertion in the ACHD population involves a careful balance of the risks and benefits. Our data show a significant proportion of patients receiving appropriate therapy indicating that ICDs were inserted appropriately.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2086-2092Informations de copyright
© 2020 Wiley Periodicals LLC.
Références
Ávila P, Mercier L-A, Dore A, et al. Adult congenital heart disease: a growing epidemic. Can J Cardiol. 2014;30:S410-S419.
Baumgartner H. Geriatric congenital heart disease: A new challenge in the care of adults with congenital heart disease? Eur Heart J. 2014;35:683-685.
Warnes CA. Adult congenital heart disease: the challenges of a lifetime. Eur Heart J. 2017;38:2041-2047.
Engelings CC, Helm PC, Abdul-Khaliq H, et al. Cause of death in adults with congenital heart disease-an analysis of the German National Register for Congenital Heart Defects. Int J Cardiol. 2016;211:31-36.
Priori SG, Blomstrom-Lundqvist C, Mazzanti A, et al. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death the Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the Europea. Eur Heart J. 2015;36:2793-2867.
Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Hear Rhythm. 2018;(15):e190-e252.
Vehmeijer JT, Koyak Z, Budts W, et al. Prevention of sudden cardiac death in adults with congenital heart disease: do the guidelines fall short? Circ Arrhythm Electrophysiol. 2017;10:e005093.
Vehmeijer JT, Brouwer TF, Limpens J, et al. Implantable cardioverter-defibrillators in adults with congenital heart disease: a systematic review and meta-analysis. Eur Heart J. 2016;37:1439-1448.
Yap S-C, Roos-Hesselink JW, Hoendermis ES, et al. Outcome of implantable cardioverter defibrillators in adults with congenital heart disease: a multi-centre study. Eur Heart J. 2007;28:1854-1861.
Witte KK, Pepper CB, Cowan JC, Thomson JD, English KM, Blackburn ME. Implantable cardioverter-defibrillator therapy in adult patients with tetralogy of Fallot. Europace. 2008;10:926-930.
Coutinho Cruz M, Viveiros Monteiro A, Portugal G, et al. Long-term follow-up of adult patients with congenital heart disease and an implantable cardioverter defibrillator. Congenit Heart Dis. 2019;14:525-533.
Koyak Z, Groot JRde, Gelder IC, et al. Implantable cardioverter defibrillator therapy in adults with congenital heart disease: who is at risk of shocks? Circ Arrhythm Electrophysiol. 2012;5:101-110.
Egbe AC, Miranda WR, Madhavan M, et al. Cardiac implantable electronic devices in adults with tetralogy of Fallot. Heart. 2019;105:538-544.
Krause U, Müller MJ, Wilberg Y, et al. Transvenous and non-transvenous implantable cardioverter-defibrillators in children, adolescents, and adults with congenital heart disease: who is at risk for appropriate and inappropriate shocks? Europace. 2019;21:106-113.
Khairy P, Harris L, Landzberg MJ, et al. Implantable cardioverter-defibrillators in tetralogy of Fallot. Circulation. 2008;117:363-370.
Backhoff D, Müller M, Ruschewski W, Paul T, Krause U. ICD therapy for primary prevention of sudden cardiac death after Mustard repair for d-transposition of the great arteries. Clin Res Cardiol. 2014;103:894-901.
Santharam S, Hudsmith L, Thorne S, Clift P, Marshall H, Bono JD. Long-term follow-up of implantable cardioverter-defibrillators in adult congenital heart disease patients: indications and outcomes. Europace. 2017;19:407-413.
Jin BK, Bang JS, Choi EY, et al. Implantable cardioverter defibrillator therapy in pediatric and congenital heart disease patients: a single tertiary center experience in Korea. Korean J Pediatr. 2013;56:125-129.
Bedair R, Babu-Narayan SV, Dimopoulos K, et al. Acceptance and psychological impact of implantable defibrillators amongst adults with congenital heart disease. Int J Cardiol. 2015;181:218-224.
Sears SF, Conti JB. Psychological aspects of cardiac devices and recalls in patients with implantable cardioverter defibrillators. Am J Cardiol. 2006;98:565-567.
Garnreiter JM, Pilcher TA, Etheridge SP, Saarel EV. Inappropriate ICD shocks in pediatrics and congenital heart disease patients: risk factors and programming strategies. Heart Rhythm. 2015;12:937-942.
Uyeda T, Inoue K, Sato J, et al. Outcome of implantable cardioverter defibrillator therapy for congenital heart disease. Pediatr Int. 2012;54:379-382.
Korte T, Köditz H, Niehaus M, Paul T, Tebbenjohanns J. High incidence of appropriate and inappropriate ICD therapies in children and adolescents with implantable cardioverter defibrillator. Pacing Clin Electrophysiol. 2004;27:924-932.